Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 3Gastrointestinal 3Sarcoma 2Other hematologic neoplasm 2Lymphoid 2CNS 2Thoracic 1Myeloid 1Genitourinary 1Endocrine 1Breast 1

Conditions

Prolactinoma 1Pituitary Neoplasms 1Growth Hormone-Secreting Pituitary Adenoma 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Adenoma, Chromophobe 1Adenoma, Basophil 1Adenoma, Acidophil 1

Interventions

Temozolomide 258Radiotherapy 147Bevacizumab 141Etoposide 68Cyclophosphamide 68Carboplatin 66Magnetic Resonance Spectroscopy 58Irinotecan 53Cisplatin 52Vincristine 45Filgrastim 43pembrolizumab 40Radiosurgery 36Nivolumab 36Radiation 34Topotecan 31Doxorubicin 30Specimen Handling 29sargramostim 28Lomustine 27Erlotinib Hydrochloride 27Peripheral Blood Stem Cell Transplantation 25Carmustine 25Thiotepa 24Everolimus 23Chemotherapy, Adjuvant 23Surgical Procedures, Operative 22Isotretinoin 22Ipilimumab 22Melphalan 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Microarray Analysis × CNS × Clear all
NCT01149850 2024-09-19

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Jonsson Comprehensive Cancer Center

Phase 2 Completed
50 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡